Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (2021 - 2025)

Stoke Therapeutics has reported Shares Outstanding over the past 5 years, most recently at $58.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 9.05% year-over-year to $58.9 million; the TTM value through Dec 2025 reached $58.9 million, up 9.05%, while the annual FY2025 figure was $58.9 million, 9.05% up from the prior year.
  • Shares Outstanding for Q4 2025 was $58.9 million at Stoke Therapeutics, up from $55.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $58.9 million in Q4 2025 and troughed at $36.9 million in Q4 2021.
  • A 5-year average of $47.2 million and a median of $45.9 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: grew 19.52% in 2024 and later grew 4.12% in 2025.
  • Year by year, Shares Outstanding stood at $36.9 million in 2021, then rose by 6.88% to $39.4 million in 2022, then increased by 16.43% to $45.9 million in 2023, then rose by 17.67% to $54.0 million in 2024, then increased by 9.05% to $58.9 million in 2025.
  • Business Quant data shows Shares Outstanding for STOK at $58.9 million in Q4 2025, $55.1 million in Q3 2025, and $54.7 million in Q2 2025.